Juno Therapeutics Inc. (JUNO)

86.96
0.09 0.10
Prev Close 86.87
Open 86.97
Day Low/High 86.90 / 87.01
52 Wk Low/High 19.62 / 87.01
Volume 3.70M
Avg Volume 4.51M
Exchange
Shares Outstanding 116.11M
Market Cap 10.10B
EPS -4.10
Div & Yield N.A. (N.A)
Jobs Watch Adds Jitters to U.S. Stocks Futures

Jobs Watch Adds Jitters to U.S. Stocks Futures

Asian markets opened lower, and futures are negatives as everyone looks for proof May's weak report was a glitch.

Juno Stock Plummets in After-Hours Trading, Clinical Trial Put on Hold After 2 Deaths

Juno Stock Plummets in After-Hours Trading, Clinical Trial Put on Hold After 2 Deaths

Juno Therapeutics (JUNO) stock is tumbling in after-hours trading Thursday after the FDA placed a clinical hold on a phase 2 clinical trial after two patients died.

Juno Patient Deaths Crash Cancer-Killing CAR-T Party

Juno Patient Deaths Crash Cancer-Killing CAR-T Party

The lead CAR-T program of Juno Therapeutics has been placed on a clinical hold by U.S. regulators following the deaths of two patients in a pivotal clinical trial.

Juno Therapeutics Reports Clinical Hold On The JCAR015 Phase II ROCKET Trial

Juno Therapeutics Reports Clinical Hold On The JCAR015 Phase II ROCKET Trial

Juno Therapeutics, Inc. (NASDAQ:JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, today announced that it has received notice from the U.

Juno Therapeutics (JUNO) Stock Coverage Initiated at Barclays

Juno Therapeutics (JUNO) Stock Coverage Initiated at Barclays

Juno Therapeutics (JUNO) stock coverage was started this morning at Barclays with an 'equal weight' rating.

Blame for Northwest Bio Collapse Lies With CEO, Not With Mythical 'Wolfpack'

Blame for Northwest Bio Collapse Lies With CEO, Not With Mythical 'Wolfpack'

A defrocked analyst brushes off the serious problems weighing on Northwest Bio. Instead, he jacks the tired 'blame the shorts' excuse to another level.

Jim Cramer's Top Takeaways: Masco, J.M. Smucker, Juno Therapeutics, Johnson & Johnson

Jim Cramer's Top Takeaways: Masco, J.M. Smucker, Juno Therapeutics, Johnson & Johnson

Masco could be setting up for a bounce, Cramer says, and Smucker is just the kind of company you should buy on a pullback.

Jim Cramer's 'Mad Money' Recap: We've Seen This 'Brexit' Movie Before

Jim Cramer's 'Mad Money' Recap: We've Seen This 'Brexit' Movie Before

Sure, we're in a bad moment but is it really worth ditching high-quality stocks to run for the hills? Cramer asks.

Juno Therapeutics (JUNO) Stock Jumps on Encouraging Clinical Data

Juno Therapeutics (JUNO) Stock Jumps on Encouraging Clinical Data

Juno Therapeutics (JUNO) stock is climbing on Monday afternoon after the biopharmaceutical company released promising clinical data for one of its leukemia treatments.

Why Juno Therapeutics (JUNO) Stock Is Spiking Today

Why Juno Therapeutics (JUNO) Stock Is Spiking Today

Juno Therapeutics (JUNO) stock is popping on Monday morning after the biopharmaceutical company announced promising clinical data for one of its leukemia treatments.

Juno Therapeutics' Investigational CAR T Cell Product Candidate JCAR015 Shows High Response Rates In Adults With B-cell ALL

Juno Therapeutics' Investigational CAR T Cell Product Candidate JCAR015 Shows High Response Rates In Adults With B-cell ALL

Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, today announced that encouraging clinical data from JCAR015, a...

Juno Therapeutics' Defined Composition CD19 Product Candidates Demonstrate Encouraging Clinical Outcomes And Tolerability

Juno Therapeutics' Defined Composition CD19 Product Candidates Demonstrate Encouraging Clinical Outcomes And Tolerability

Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, today announced that its investigational chimeric antigen...

Are These 3 Speculative Short-Covering Rally Trades Worth the Risk?

Are These 3 Speculative Short-Covering Rally Trades Worth the Risk?

These three stocks have large short interest and are poised to break above key resistance levels. Here's how to trade them from here.

Juno Therapeutics To Present At June 2016 Investor Conferences

Juno Therapeutics To Present At June 2016 Investor Conferences

Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will webcast its presentations at two investor conferences in June.

Ziopharm Subpar Cancer Therapies Can't Support Lofty Market Valuation

Ziopharm Subpar Cancer Therapies Can't Support Lofty Market Valuation

Ziopharm is its own mini biotech bubble, held aloft unjustifiably because of its interlocking relationship with Intrexon, the synthetic biology company majority-owned by R.J. Kirk.

Juno Therapeutics To Highlight Advancing Immuno-oncology Portfolio At The 2016 American Society Of Clinical Oncology Annual Meeting

Juno Therapeutics To Highlight Advancing Immuno-oncology Portfolio At The 2016 American Society Of Clinical Oncology Annual Meeting

Juno Therapeutics, Inc. (NASDAQ:JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, today announced that in partnership with its collaborators it will...

Biotech Stock Mailbag: Why Intrexon CEO R.J. Kirk Should Not Be Trusted

Biotech Stock Mailbag: Why Intrexon CEO R.J. Kirk Should Not Be Trusted

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Juno Therapeutics Reports First Quarter 2016 Financial Results

Juno Therapeutics Reports First Quarter 2016 Financial Results

Juno Therapeutics, Inc. (NASDAQ:JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, today reported financial results and business highlights for the...

Juno Therapeutics To Present At The Bank Of America Merrill Lynch 2016 Health Care Conference

Juno Therapeutics To Present At The Bank Of America Merrill Lynch 2016 Health Care Conference

Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will webcast its presentation at the Bank of America Merrill Lynch 2016 Health Care Conference at 8:40 a.

Juno Therapeutics To Report First Quarter 2016 Financial Results On Monday, May 9

Juno Therapeutics To Report First Quarter 2016 Financial Results On Monday, May 9

Juno Therapeutics, Inc. (NASDAQ: JUNO) will announce financial results for the first quarter 2016 on Monday, May 9, 2016, after the close of U.

Juno's Investigational CAR T Cell Product Candidates JCAR018 And JTCR016 Demonstrate Encouraging Clinical Responses In Patients With B-Cell And Mesothelioma Cancers

Juno's Investigational CAR T Cell Product Candidates JCAR018 And JTCR016 Demonstrate Encouraging Clinical Responses In Patients With B-Cell And Mesothelioma Cancers

Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, today announced, in partnership with its collaborators, early...

Juno Therapeutics Announces Data Presentations At The American Association For Cancer Research Annual Meeting

Juno Therapeutics Announces Data Presentations At The American Association For Cancer Research Annual Meeting

Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, today announced the Company, in partnership with its...

Celgene And Juno Announce Celgene Exercised Option To Develop And Commercialize CD19-directed Product Candidates

Celgene And Juno Announce Celgene Exercised Option To Develop And Commercialize CD19-directed Product Candidates

Celgene Corporation (NASDAQ: CELG) and Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that Celgene exercised its option to develop and commercialize the Juno CD19 program outside North America and China.

Juno Therapeutics To Present At March 2016 Investor Conferences

Juno Therapeutics To Present At March 2016 Investor Conferences

Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will webcast its presentations at two investor conferences in March.

JUNO THERAPEUTICS (JUNO) SHAREHOLDER ALERT - Andrews & Springer LLC Is Investigating Juno Therapeutics, Inc. For Potential Breaches Of Fiduciary Duty

JUNO THERAPEUTICS (JUNO) SHAREHOLDER ALERT - Andrews & Springer LLC Is Investigating Juno Therapeutics, Inc. For Potential Breaches Of Fiduciary Duty

Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against Juno Therapeutics, Inc.

Juno Therapeutics Reports Fourth Quarter And 2015 Financial Results

Juno Therapeutics Reports Fourth Quarter And 2015 Financial Results

Juno Therapeutics, Inc. (NASDAQ:JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, today reported business highlights and financial results for the...

Juno Therapeutics, Seattle Cancer Care Alliance And Fred Hutchinson Cancer Research Center Announce New Immuno-oncology Clinical Trials Unit

Juno Therapeutics, Seattle Cancer Care Alliance And Fred Hutchinson Cancer Research Center Announce New Immuno-oncology Clinical Trials Unit

Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, and Fred Hutchinson Cancer Research Center (Fred Hutch) today...

Juno Therapeutics To Report Full Year And Fourth Quarter 2015 Financial Results On Monday, February 29

Juno Therapeutics To Report Full Year And Fourth Quarter 2015 Financial Results On Monday, February 29

Juno Therapeutics, Inc. (NASDAQ: JUNO) will announce financial results for the fourth quarter and year ended December 31, 2015 on Monday, February 29, 2016, after the close of U.

5 Breakout Stocks to Trade for Big Gains

5 Breakout Stocks to Trade for Big Gains

These stocks looks ready to break out and trade higher from current levels.

Juno Therapeutics To Present At The Leerink Partners 5th Annual Global Healthcare Conference

Juno Therapeutics To Present At The Leerink Partners 5th Annual Global Healthcare Conference

Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will webcast its presentation at the Leerink Partners 5 th Annual Global Healthcare Conference at 10:40 a.